The Overwatch 2 developers have revealed which heroes are being banned the most in every role, with one character not being playable in over 90% of games.
In Season 16, Overwatch finally introduced hero bans, giving players the opportunity to shift the game’s meta in wildly different ways by removing certain characters from the equation.
The bans have been seen as a major success so far, albeit some players, such as Mercy mains, have been upset with the feature as they struggle to use other heroes.
Article continues after ad
On May 23, the devs finally unveiled data for hero bans on console and PC, with one hero standing high above the rest in terms of how often they’re banned.
Sombra is banned in over 90% of Overwatch 2 games on console
In a May 2025 blog post, the devs revealed that Sombra has an 85% ban rate on PC – while on console, it’s even higher at 93%.
Sombra has been an incredibly controversial hero despite receiving a handful of reworks, but common issues with her kit have remained throughout her introduction to the game back in 2016.
Article continues after ad
Article continues after ad
Primarily, fans dislike playing against a hero who has both invisibility and a disable as part of their kit – something that has remained in all variations of the Talon hacker.
In second place on PC, it’s Zarya at 59%, followed by Doomfist at 43%. On console, it’s Zarya at 57% and Symmetra at 23%.
Meanwhile, for players who are Masters and above on PC, Freja is the most banned hero. However, Sombra remains the most banned hero in Masters+ on console.
Article continues after ad
As for supports, Ana is the most banned on PC, while Mercy has been banned the most on console.
The developers say that this data will help them when it comes to future balance patches, but it’s important to note that ban statistics alone won’t be responsible for which heroes get nerfs and buffs.
That said, it certainly seems like Sombra could be in line for yet another rework down the road based on these overwhelming stats.
Article continues after ad
Article continues after ad
